Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

150 mg orally twice daily; ≤4 × 28-day cycles

2 mg orally once daily; same duration

160 mg orally twice daily; ≤4 cycles

retrospective, 400 mg orally once daily; ≤4 cycles

24 mg orally once daily; ≤4 cycles

Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.

12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)

200 mg IV infusion every 3 weeks; ≤4 cycles

200 mg IV infusion every 3 weeks; ≤4 cycles

Cabozantinib 60 mg orally once daily, continuous 28-day cycles.

China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).

Conversion Surgery if resectable